The unintended burden of increased prostate cancer detection associated with prostate cancer screening and diagnosis.

The increasing incidence of prostate cancer is associated with the intensity of screening for prostate-specific antigen. Although some men may benefit from the early detection of prostate cancer through screening, all men diagnosed with prostate cancer experience an effect on their mental and physical well-being and that of their families. In light of the recent publication of the United States Preventive Services Task Force recommendations concerning prostate-specific antigen testing, this article reviews the quality-of-life implications of prostate cancer screening and diagnosis, and explores risk reduction in screened men as a potential strategy to manage these issues.

[1]  R A Stephenson,et al.  Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. , 2000, Journal of the National Cancer Institute.

[2]  A. Evans,et al.  Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. , 2007, Contemporary clinical trials.

[3]  F. Hamdy,et al.  Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. , 2008, The Lancet. Oncology.

[4]  S. Bloch,et al.  Psychological adjustment of men with prostate cancer: a review of the literature , 2007, BioPsychoSocial medicine.

[5]  D. Penson,et al.  Cross‐sectional and longitudinal comparisons of health‐related quality of life between patients with prostate carcinoma and matched controls , 2004, Cancer.

[6]  Brian J. Miles,et al.  A Decision Analysis for Treatment of Clinically Localized Prostate Cancer , 1997 .

[7]  D. Penson Quality of Life After Therapy for Localized Prostate Cancer , 2007, Cancer journal.

[8]  S. Arver,et al.  Waning sexual function--the most important disease-specific distress for patients with prostate cancer. , 1996, British Journal of Cancer.

[9]  Peter H Gann,et al.  Prostate specific antigen best practice statement: 2009 update. , 2009, The Journal of urology.

[10]  D. Radice,et al.  Quality of Life and Economic Considerations in the Management of Prostate Cancer , 2012, PharmacoEconomics.

[11]  D. Meltzer,et al.  The role of anxiety in prostate carcinoma , 2005, Cancer.

[12]  Ian M Thompson,et al.  Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker , 2004, Cancer.

[13]  M. Barry,et al.  A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. , 1993, JAMA.

[14]  PSA testing: public policy or private penchant? , 2006, JAMA.

[15]  J. Manson,et al.  Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. , 2009, JAMA.

[16]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[17]  D. Tindall,et al.  Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. , 2004, The Journal of urology.

[18]  S. Ramsey,et al.  Why do men choose one treatment over another? , 2006, Cancer.

[19]  Michael M Lieber,et al.  Journal Review , 2003, International Society of Hair Restoration Surgery.

[20]  Pascal Pommier,et al.  Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study. , 2007, International journal of radiation oncology, biology, physics.

[21]  M. Issa,et al.  An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. , 2006, The American journal of managed care.

[22]  E. Berthelet,et al.  Prospective evaluation of the prevalence and severity of fatigue in patients with prostate cancer undergoing radical external beam radiotherapy and neoadjuvant hormone therapy. , 2006, The Canadian journal of urology.

[23]  I. Thompson,et al.  Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling Approach , 2008, Cancer Prevention Research.

[24]  B. Weber,et al.  Urinary, sexual, and bowel dysfunction and bother after radical prostatectomy. , 2007, Urologic nursing.

[25]  R. Weichselbaum,et al.  Potency preservation following conformal radiotherapy for localized prostate cancer: impact of neoadjuvant androgen blockade, treatment technique, and patient-related factors. , 1999, The cancer journal from Scientific American.

[26]  David C. Smith,et al.  Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[28]  F. Hamdy,et al.  Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. , 2006, The Journal of urology.

[29]  Thomas Wheeler,et al.  An analysis of men with clinically localized prostate cancer who deferred definitive therapy. , 2004, The Journal of urology.

[30]  R. A. Robinson,et al.  Patients' perceptions of quality of life after treatment for early prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Matthew R Cooperberg,et al.  Contemporary trends in low risk prostate cancer: risk assessment and treatment. , 2007, The Journal of urology.

[32]  Donald E Bailey,et al.  Active surveillance for early‐stage prostate cancer , 2008, Cancer.

[33]  L. Gomella Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality‐of‐life issues , 2007, BJU international.

[34]  I. Thompson Chemoprevention of prostate cancer: agents and study designs. , 2007, The Journal of urology.

[35]  D. Theodorescu,et al.  Determinants of long‐term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer , 2004, BJU international.

[36]  A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. , 1993 .

[37]  Quality of life and emotional distress in advanced prostate cancer survivors undergoing chemotherapy , 2004, Health and quality of life outcomes.

[38]  J. Ware,et al.  Health-related quality of life among patients with metastatic prostate cancer. , 1997, Urology.

[39]  Andrew J. Vickers,et al.  Prostate-specific antigen and prostate cancer: prediction, detection and monitoring , 2008, Nature Reviews Cancer.

[40]  J. Gohagan,et al.  Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. , 2005, Journal of the National Cancer Institute.

[41]  E. Giovannucci,et al.  The association of treatment‐related symptoms with quality‐of‐life outcomes for localized prostate carcinoma patients , 2002, Cancer.

[42]  J. Gore,et al.  Quality of life after surgery, external beam irradiation, or brachytherapy for early‐stage prostate cancer , 2007, Cancer.

[43]  D. Lubeck,et al.  Quality of life before death for men with prostate cancer: results from the CaPSURE database. , 2001, The Journal of urology.

[44]  H. D. de Koning,et al.  Prostate cancer diagnosis: the impact on patients' mental health. , 2006, European journal of cancer.

[45]  V. Moyer,et al.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[46]  Susan T. Stewart,et al.  Utilities For Prostate Cancer Health States in Men Aged 60 and Older , 2005, Medical care.

[47]  P. Stone,et al.  A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  J. Crowley,et al.  Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). , 2009, JAMA.